Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab ± ipilimumab with TACE in intermediate-stage hepatocellular carcinoma
2019-002790-58Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Nivolumab + ipilimumab + TACE, Nivolumab + TACE and Placebo + TACE (3 arms). Primary endpoints: Incidence of adverse events and Incidence of serious adverse events. Started Jun 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-002790-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002790-58.